Literature DB >> 32719501

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma.

Eugenio Galli1,2, Vincent Allain3, Roberta Di Blasi4,5, Sophie Bernard4, Laetitia Vercellino6, Florence Morin3, Hannah Moatti4, Sophie Caillat-Zucman3, Sylvie Chevret7, Catherine Thieblemont4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32719501     DOI： 10.1038/s41409-020-01006-x

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

Review 1.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

2.  Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF).

Authors:  Hartmut Link
Journal:  Support Care Cancer       Date:  2022-09       Impact factor: 3.359

Review 3.  CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias.

Authors:  Alankrita Taneja; Tania Jain
Journal:  EJHaem       Date:  2021-11-21

4.  G-CSF induces CD15+ CD14+ cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment.

Authors:  Ebtehag Maneta; Livingstone Fultang; Jemma Taylor; Matthew Pugh; William Jenkinson; Graham Anderson; Arri Coomarasamy; Mark D Kilby; David M Lissauer; Francis Mussai; Carmela De Santo
Journal:  Clin Transl Immunology       Date:  2022-05-17

5.  [How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management].

Authors:  W B Qian; H Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14

6.  Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy.

Authors:  Limin Xing; Yihao Wang; Hui Liu; Shan Gao; Qing Shao; Lanzhu Yue; Zhaoyun Liu; Huaquan Wang; Zonghong Shao; Rong Fu
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

7.  CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.

Authors:  Kai Rejeski; Ariel Perez; Pierre Sesques; Eva Hoster; Carolina Berger; Liv Jentzsch; Dimitrios Mougiakakos; Lisa Frölich; Josephine Ackermann; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Laurent Jallades; Boris Fehse; Christoph Faul; Philipp Karschnia; Oliver Weigert; Martin Dreyling; Frederick L Locke; Michael von Bergwelt-Baildon; Andreas Mackensen; Wolfgang Bethge; Francis Ayuk; Emmanuel Bachy; Gilles Salles; Michael D Jain; Marion Subklewe
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

Review 8.  Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.

Authors:  Naman Sharma; Patrick M Reagan; Jane L Liesveld
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.